“My husband was diagnosed with wet AMD. Thanks to a quick referral, he began treatment promptly. Dr. Lagonigro was professional, knowledgeable, and concise. We are so grateful. 5⭐️⭐️⭐️⭐️⭐️”
How Many Eye Injections Will You Need?
What Conditions Require Ongoing Injections
Anti-VEGF injections are used for several retinal conditions, each with its own pattern of disease activity and treatment frequency. Knowing which condition you have and how it tends to behave over time helps set realistic expectations.
Wet AMD is the most common reason for long-term anti-VEGF treatment. In wet AMD, abnormal blood vessels grow beneath the retina and leak fluid or blood, threatening central vision. Treatment focuses on drying out the retina and keeping it dry, which for most people means an ongoing schedule measured in years.
Diabetic macular edema (swelling of the central retina caused by leaking blood vessels related to diabetes) also typically requires repeated injections. The pattern is similar to wet AMD: a more intensive early phase to reduce swelling, followed by a maintenance phase spaced as far apart as the eye safely allows. Blood sugar control plays an important role in how the eye responds.
A retinal vein occlusion occurs when a vein carrying blood away from the retina becomes blocked, causing fluid to build up. Anti-VEGF injections reduce that fluid and help protect vision. Some eyes resolve with a limited course of treatment, while others need longer-term management, depending on whether fluid continues to accumulate.
The Three Main Injection Schedules
The schedule your Retina Specialist chooses has a direct effect on how many injections you receive each year. There are three main approaches, and each has real advantages and trade-offs worth understanding.
A fixed schedule means injections are given at a set interval, commonly every four or eight weeks, regardless of how the eye looks between visits. This approach provides steady drug levels and was the method used in the original clinical trials that proved anti-VEGF treatment works. It tends to produce the most injections per year and is often used at the start of treatment to gain control quickly.
Treat and extend is now one of the most widely used approaches because it tries to reduce the total number of injections while keeping the disease quiet. Your Retina Specialist treats at every visit but gradually lengthens the interval when the retina stays dry, and shortens it again if fluid returns. Someone with a calm eye may eventually reach intervals of three or four months, while a more active eye is kept closer together. Over time, this often means noticeably fewer injections without losing control of the disease.
With as-needed dosing, you receive several initial monthly injections and then return for regular monitoring visits. An additional injection is given only when the retina shows new fluid or bleeding. This approach can reduce the total number of injections, but it relies on frequent check-up visits so that any flare is caught and treated early. The main trade-off is that waiting for a flare can sometimes allow a small amount of damage before treatment restarts.
Some newer anti-VEGF medicines are designed to remain active in the eye for longer, which can reduce how many injections are needed each year. Vabysmo (faricimab), for example, can be given as infrequently as every 16 weeks in some patients with wet AMD after an initial loading phase. Longer intervals do not suit every eye, and some still need frequent treatment, but for many people these options mean fewer visits for the same level of protection. Ask your Retina Specialist whether a longer-acting medicine is appropriate for your situation.
What the Long-Term Numbers Show
Long-term studies give a realistic picture of what ongoing treatment looks like in practice. The first year is almost always the busiest, and later years tend to be lighter as the disease comes under control.
Early treatment focuses on drying out the retina, so injections are clustered close together. As the eye stabilizes, most Retina Specialists begin stretching the intervals. It is common to receive more injections in the first year than in any year that follows. Seeing the pace ease over time is expected, though it is not guaranteed for every eye.
Long-term follow-up data from major clinical trials show that ongoing treatment in later years typically averages around four to five injections per year for many patients, compared with the near-monthly frequency of the early phase. Real-world numbers vary widely, from a handful to dozens over many years, depending on how active the disease remains. The takeaway is not a target number to hit, but a pattern: an ongoing commitment that is usually lighter after the first intensive stretch.
More important than the injection count is what the treatment protects. Long-term studies show that many people maintain useful vision with consistent ongoing treatment, though outcomes vary from person to person. Some hold their vision well for years, while others lose ground despite excellent care, often due to scarring or thinning of the retina that injections cannot undo. Your Retina Specialist can give you a more personal picture after examining your specific eye.
Side Effects and Safety With Repeated Injections
Anti-VEGF injections have a strong safety record, especially when performed under careful, sterile conditions. Most side effects are mild and short-lived, but a small number of serious problems can occur and are important to recognize.
After an injection, it is normal to notice a small red spot on the white of the eye from a minor surface bleed, brief discomfort or a gritty feeling, a few new floaters, or a temporary rise in eye pressure within the first hour. These effects are expected, usually settle on their own within a day or two, and do not generally become worse with repeated injections over time.
A small number of people experience serious complications after an injection, including endophthalmitis (a rare but severe infection inside the eye) or retinal detachment. These events are uncommon, and when caught early they are treatable. The key is recognizing the warning signs quickly.
- Eye pain that is getting worse rather than better after the first day
- Growing redness or new discharge from the eye
- Vision that is dropping or a new dark shadow appearing
- A sudden large shower of new floaters or flashing lights
If any of these occur after an injection, contact your Retina Specialist the same day rather than waiting for your next scheduled visit.
Each injection carries a small, mostly consistent per-injection risk rather than a growing one. More injections mean more individual chances for a rare event, but the risk level at each individual injection stays low. Before every dose, your care team screens for active infection or inflammation in the eye, which are reasons to delay treatment. For most people, the well-established benefit of protecting vision outweighs the small risk at each injection, which is why long-term treatment is recommended.
When an Injection Should Be Delayed
There are situations when the safest decision is to postpone a scheduled injection. Knowing when and why a dose may be delayed can help you understand your treatment plan more fully.
An anti-VEGF injection should not be given when there is an active infection in or around the eye, inflammation inside the eye, or a known allergy to the specific medicine being used. A red, painful, or discharging eye, a stye, or a recent eye infection are reasons your Retina Specialist may delay that dose until the problem resolves. A brief, deliberate pause is a careful precaution, not a setback.
Changes in your overall health can affect the timing or choice of treatment as well. Recent cardiovascular events, new blood-thinning medications, or plans to become pregnant are all worth mentioning at your visit. None of these automatically stop your injections, but they help your Retina Specialist make the most informed decision about your care. The habit to build is simple: mention anything new in your health or medicines at each visit, even if it seems unrelated to your eyes.
Frequently Asked Questions
Below are answers to questions we hear often from patients managing long-term injection treatment. These answers focus on decision guidance and practical considerations.
For most people with wet AMD or chronic diabetic macular edema, treatment is long-term, measured in years, though the pace usually eases after the early intensive phase. A small number of eyes eventually become quiet enough that injections can be spaced very widely or paused under close supervision. Stopping on your own without guidance is risky, because the disease can flare before you notice a change in vision. If you are hoping to reduce frequency or pause treatment, discuss it with your Retina Specialist so any changes can be tested safely through gradual interval extension.
Feeling fine does not mean the disease is inactive, because fluid can build up in the retina without causing noticeable symptoms at first. The effect of each injection fades over weeks, and a missed or significantly delayed dose creates a window during which leaking can resume. Vision lost in that window is often difficult to recover. An occasional prompt reschedule is generally manageable, but a pattern of skipped visits is one of the more common reasons vision slips during otherwise well-controlled treatment. If appointments are hard to keep, let your care team know so alternatives can be explored.
The decision is based on what your eye shows at each visit, not the calendar alone. Your Retina Specialist will check your vision and typically perform an OCT scan (optical coherence tomography), which reveals fluid in the retina in fine detail. When the retina is consistently dry, the interval is extended by a small increment at the next visit. If fluid returns, the interval is shortened again. This step-by-step process is what makes treat-and-extend an individualized approach, and it is precisely why keeping every monitoring visit is what allows fewer injections over time rather than more.
It can for some patients. Longer-acting medicines are designed to maintain disease control for more weeks between doses, so they may lower your annual injection count while providing similar protection. Whether switching makes sense depends on how active your disease currently is, whether your eye tolerates longer gaps, and how you are responding to your current medicine. It is a worthwhile question to raise directly with your Retina Specialist, who can weigh those factors against the appeal of fewer clinic visits.
Only if both eyes have a condition requiring treatment. Many people begin with one affected eye, and because conditions like wet AMD often eventually involve the other eye, your Retina Specialist will monitor the unaffected eye at your regular visits. If disease develops there, each eye is managed on its own schedule based on its own activity level. Having one eye treated does not mean the other definitely will need treatment, but it does raise the odds enough that careful watching is worthwhile.
Coming prepared makes your visits more productive and helps you feel more in control of your treatment. Consider asking your Retina Specialist which scheduling approach is being used for your eye and why, roughly how many injections you might expect over the next year, whether a longer-acting medicine could reduce your visit frequency, what specific signs should prompt a same-day call, and what happens to your vision if a dose is delayed. Writing these down beforehand means you are less likely to forget them in the moment.
Care for Your Retina on the Delmarva Peninsula
Our team at Atlantic Retina Center is fellowship-trained and board-certified in vitreoretinal surgery, focused exclusively on the retina, vitreous, and macula. We use detailed retinal imaging at every visit to track how your eye is responding over time, so your treatment plan is always based on what your eye is actually showing us. If you have questions about your injection schedule or would like a specialist evaluation, we welcome you to reach out and schedule a visit at one of our offices across the region.